Alivus Life Sciences Limited — Board Meeting, 15-05-2025: Outcome of Board Meeting

Alivus Life Sciences has announced a board meeting on May 15, 2025, approving the financial results for the quarter and half-year. Consolidated revenue hit ₹2,386.88 Cr with a profit after tax of ₹48.56 Cr, slightly up from last year’s ₹47.09 Cr. EPS is ₹39.63. The board proposed a final dividend of 250% (₹5 per share). Total assets grew to ₹3,411 Cr, driven by higher inventory and receivables, while net cash from operations was a robust ₹555 Cr, reflecting strong operational cash flow.